Phase II Study of IRD (Ixazomib, Lenalidomide, Dexamethasone) Post Autologous Stem Cell Transplantation Followed by Maintenance Ixazomib or Lenalidomide for Multiple Myeloma
Summary
The registered summary isn't in our current data snapshot. Read it on the ClinicalTrials.gov record ↗. Why? →
Investigators
The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.
- Ravi Vij, M.D.
Washington University School of Medicine
Principal Investigator
A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.
Sites
10 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.
- City of Hope
Duarte, California, United States
- University of California, San Francisco
San Francisco, California, United States
- Colorado Blood Cancer Institute
Denver, Colorado, United States
- Emory University - Winship Cancer Institute
Atlanta, Georgia, United States
- Karmanos Cancer Institute
Detroit, Michigan, United States
- Mayo Clinic
Rochester, Minnesota, United States
- Washington University School of Medicine
St Louis, Missouri, United States
- Icahn School of Medicine at Mount Sinai
New York, New York, United States
- Ohio State University Comprehensive Cancer Center
Columbus, Ohio, United States
- Tennessee Oncology, Pllc
Nashville, Tennessee, United States
Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.
Drugs studied
No drug or biological interventions are in our data for this study — it may test a procedure, device or behavioral intervention, or the intervention list isn't in our current snapshot. See the registry record ↗. Why? →
Registration & key dates
Registry attributes as recorded on the ClinicalTrials.gov study record.
- Start
- 20 Jan 2015
- Primary completion
- 5 Feb 2020
- Completion
- 31 Aug 2026
- Last update posted
- 10 Nov 2025
- Registered enrollment
- 236
- Registry id
- NCT02253316
Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 12 Jul 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.